Telix Pharmaceuticals 第一季度業績強勁增長
Telix Pharmaceuticals Reports Strong Q1 Growth
Telix Pharmaceuticals 報告了2026年強勁的開局，在其第一季市場更新中宣布了強大的財務與營運動能。
Telix Pharmaceuticals has reported an impressive start to 2026, announcing strong financial and operational momentum in its Q1 market update.
這項成就的主要驅動力為其精準醫學部門，該部門在Illuccix和Gozellix等PSMA顯影產品高需求的推動下，收入達到1.86億美元。
A major driver of this success was its Precision Medicine segment, which brought in US$186 million, fueled by high demand for its PSMA imaging products like Illuccix and Gozellix.
目前，Illuccix已在21個國家上市，凸顯了該公司不斷擴大的全球版圖。
Currently, Illuccix is available in 21 countries, highlighting the firm's expanding global reach.
治療候選藥物TLX591-Tx的第三期ProstACT研究已達到安全性里程碑，該公司也已推進了Pixclara和Pixlumi的法規申報作業。
The Phase 3 ProstACT study for the therapy candidate TLX591-Tx reached its safety milestones, and the company has progressed with regulatory filings for Pixclara and Pixlumi.
隨著全年營收預測設定在9.5億至9.7億美元之間，管理層對維持其在放射性藥物行業的領導地位充滿信心。
With full-year revenue guidance set between US$950 million and US$970 million, management remains confident in maintaining its leadership within the radiopharmaceutical industry.
這種增長體現了Telix有效的戰略與致力於推動全球精準醫學的承諾。
This growth demonstrates Telix's effective strategy and commitment to advancing precision medicine worldwide.
